tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST), Nyxoah (NYXH) and Zoetis (ZTS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Envista Holdings (NVSTResearch Report), Nyxoah (NYXHResearch Report) and Zoetis (ZTSResearch Report).

Envista Holdings (NVST)

In a report released today, Jason Bednar from Piper Sandler maintained a Hold rating on Envista Holdings, with a price target of $23.00. The company’s shares closed last Monday at $19.14, close to its 52-week low of $18.96.

According to TipRanks.com, Bednar has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.3% and a 37.6% success rate. Bednar covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Merit Medical Systems, and Alpha Tau Medical Ltd.

Currently, the analyst consensus on Envista Holdings is a Hold with an average price target of $23.50.

See Insiders’ Hot Stocks on TipRanks >>

Nyxoah (NYXH)

In a report released today, Jonathan Block from Stifel Nicolaus maintained a Buy rating on Nyxoah, with a price target of $27.00. The company’s shares closed last Monday at $8.90.

According to TipRanks.com, Block is a 4-star analyst with an average return of 6.7% and a 51.0% success rate. Block covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Elanco Animal Health, and Patterson Companies.

Nyxoah has an analyst consensus of Strong Buy, with a price target consensus of $19.29.

Zoetis (ZTS)

Piper Sandler analyst David Westenberg reiterated a Buy rating on Zoetis today and set a price target of $195.00. The company’s shares closed last Monday at $149.77, close to its 52-week low of $148.48.

According to TipRanks.com, Westenberg is a 1-star analyst with an average return of -2.1% and a 40.6% success rate. Westenberg covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, Elanco Animal Health, and Pacific Biosciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zoetis with a $215.43 average price target, which is a 42.6% upside from current levels. In a report issued on April 2, Stifel Nicolaus also maintained a Buy rating on the stock with a $195.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NVST:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles